« The Fall of General Motors
Tired of Apple Rumors »

Those with stakes in GlaxoSmithKline (NYSE: GSK) were pleased this morning as the stock rose on account of the FDA’s approval of Lamictal XR (“extended release”) . The drug, aimed at epilepsy patients thirteen years of age and older, is intended to reduce seizures in patients who have had unsuccessful results with other therapies.

Legal

As a third year medical student at Baylor College of Medicine, my posts are intended to educate others and share my experiences from this incredible journey without violating patient privacy at all costs. These blurbs are not to serve as a replacement for recommendations provided by licensed physicians under any circumstance.